Author Correction: Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer (Scientific Reports, (2015), 5, 1, (16053), 10.1038/srep16053);Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Pan, Bo ^a   Shen, Jing ^a   Cao, Jingyan ^a   Zhou, Yongxu ^a   Shang, Lihua ^a   Jin, Shi ^a   Cao, Shoubo ^a   Che, Dehai ^a   Liu, Fang ^a   Yu, Yan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN BINDING PROTEIN; CCDC88A PROTEIN, HUMAN; CONDITIONED MEDIUM; CYTOKINE; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; MESSENGER RNA; RECOMBINANT PROTEIN; STAT3 PROTEIN; VASCULOTROPIN A; VESICULAR TRANSPORT PROTEIN;

AGED; ANGIOGENESIS; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL SURVIVAL; CONDITIONED MEDIUM; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); NON SMALL CELL LUNG CANCER; PATHOLOGY; PHARMACOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; CULTURE MEDIA, CONDITIONED; CYTOKINES; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-17; LUNG NEOPLASMS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, INTERLEUKIN-17; RECOMBINANT PROTEINS; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VESICULAR TRANSPORT PROTEINS;

EID: 84946567263     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-020-65650-5     Document Type: Erratum

References (50)

1. Smith, R. A., Cokkinides, V. and Brawley, O. W. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 59, 27-41 (2009).
2. Sun, S., Schiller, J. H., Spinola, M. and Minna, J. D. New molecularly targeted therapies for lung cancer. J Clin Invest 117, 2740-50 (2007).
3. Mantovani, A., Romero, P., Palucka, A. K. and Marincola, F. M. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 371, 771-83 (2008).
4. Solan, M. J. and Werner-Wasik, M. Prognostic factors in non-small cell lung cancer. Semin Surg Oncol 21, 64-73 (2003).
5. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1, 27-31 (1995).
6. Carmeliet, P. and Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249-57 (2000).
7. Miossec, P., Korn, T. and Kuchroo, V. K. Interleukin-17 and type 17 helper T cells. N Engl J Med 361, 888-98 (2009).
8. Kryczek, I. et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114, 1141-9 (2009).
9. Steiner, G. E. et al. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 56, 171-82 (2003).
10. Zhang, B. et al. The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun 374, 533-7 (2008).
11. Chang, S. H. et al. T helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci USA 111, 5664-9 (2014).
12. Pan, B. et al. Interleukin-17 levels correlate with poor prognosis and vascular endothelial growth factor concentration in the serum of patients with non-small cell lung cancer. Biomarkers 20, 232-9 (2015).
13. Numasaki, M. et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 101, 2620-7 (2003).
14. Tartour, E. et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 59, 3698-704 (1999).
15. Niu, G. et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21, 2000-8 (2002).
16. Kortylewski, M. and Yu, H. Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol 20, 228-33 (2008).
17. Dunkel, Y. et al. STAT3 protein up-regulates Galpha-interacting vesicle-associated protein (GIV)/Girdin expression, and GIV enhances STAT3 activation in a positive feedback loop during wound healing and tumor invasion/metastasis. J Biol Chem 287, 41667-83 (2012).
18. Ghosh, P., Garcia-Marcos, M., Bornheimer, S. J. and Farquhar, M. G. Activation of Galphai3 triggers cell migration via regulation of GIV. J Cell Biol 182, 381-93 (2008).
19. Iida, T. et al. Tumor-infiltrating CD4+ Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer. Oncol Rep 25, 1271-7 (2011).
20. Liu, J. et al. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 407, 348-54 (2011).
21. Zhang, J. P. et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 50, 980-9 (2009).
22. He, S. et al. Distribution and clinical significance of Th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients. Int J Mol Sci 12, 7424-37 (2011).
23. Numasaki, M. et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 175, 6177-89 (2005).
24. Yu, H., Kortylewski, M. and Pardoll, D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7, 41-51 (2007).
25. Cailleau, R., Olive, M. and Cruciger, Q. V. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 14, 911-5 (1978).
26. Garcia-Marcos, M. et al. Expression of GIV/Girdin, a metastasis-related protein, predicts patient survival in colon cancer. FASEB J 25, 590-9 (2011).
27. Weng, L., Enomoto, A., Ishida-Takagishi, M., Asai, N. and Takahashi, M. Girding for migratory cues: roles of the Akt substrate Girdin in cancer progression and angiogenesis. Cancer Sci 101, 836-42 (2010).
28. Wang, L. et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206, 1457-64 (2009).
29. Gu, F. M. et al. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma. Mol Cancer 10, 150 (2011).
30. Benchetrit, F. et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 99, 2114-21 (2002).
31. Inozume, T., Hanada, K., Wang, Q. J. and Yang, J. C. IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells. J Immunother 32, 109-17 (2009).
32. Gaffen, S. L. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 9, 556-67 (2009).
33. Ogura, H. et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 29, 628-36 (2008).
34. Gao, Q. et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 15, 971-9 (2009).
35. Xie, T. X. et al. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 66, 3188-96 (2006).
36. Gong, W. et al. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res 11, 1386-93 (2005).
37. Wei, D. et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22, 319-29 (2003).
38. Coultas, L., Chawengsaksophak, K. and Rossant, J. Endothelial cells and VEGF in vascular development. Nature 438, 937-45 (2005).
39. Pappu, R., Ramirez-Carrozzi, V. and Sambandam, A. The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases. Immunology 134, 8-16 (2011).
40. Rane, S. G. and Reddy, E. P. JAKs, STATs and Src kinases in hematopoiesis. Oncogene 21, 3334-58 (2002).
41. Levy, D. E. and Darnell, J. E. Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3, 651-62 (2002).
42. Hu, Q. et al. Periostin Mediates TGF-beta-Induced Epithelial Mesenchymal Transition in Prostate Cancer Cells. Cell Physiol Biochem 36, 799-809 (2015).
43. Kumar, J. et al. Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer. Br J Cancer 110, 133-45 (2014).
44. Chakraborty, A. et al. Granulocyte colony-stimulating factor activation of Stat3 alpha and Stat3 beta in immature normal and leukemic human myeloid cells. Blood 88, 2442-9 (1996).
45. Onishi, R. M. and Gaffen, S. L. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 129, 311-21 (2010).
46. Jiang, P. et al. An actin-binding protein Girdin regulates the motility of breast cancer cells. Cancer Res 68, 1310-8 (2008).
47. Liu, C. et al. Girdin protein: a new potential distant metastasis predictor of breast cancer. Med Oncol 29, 1554-60 (2012).
48. Yang, X. R. et al. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin Cancer Res 14, 3850-9 (2008).
49. Chen, X. et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 69, 348-54 (2010).
50. Huh, J. E. et al. Bee venom inhibits tumor angiogenesis and metastasis by inhibiting tyrosine phosphorylation of VEGFR-2 in LLC-tumor-bearing mice. Cancer Lett 292, 98-110 (2010).